ArticleBMJ supportive & palliative care2026
Outpatient rapid drug desensitisation for chemotherapy and biologic agents: high success rates in a large single-centre cohort study.
Article in BMJ supportive & palliative care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesWe evaluated rapid drug desensitisation (RDD) protocols at Memorial Sloan Kettering Cancer Center (MSK) to determine completion rates and characterise hypersensitivity reaction (HSR) phenotypes using clinical features and biomarker data. This study addresses an important gap by assessing an expanded range of antineoplastic agents, incorporating biomarkers such as tryptase and interleukin-6, and evaluating outcomes under updated outpatient oncology and allergy-co-managed desensitisation pathways.
methodsThis retrospective, single-centre descriptive study included adult patients who underwent RDD to any chemotherapeutic or biologic agent between 1 October 2023 and 31 October 2024, following a documented HSR. RDD 'success' was defined as completion of at least one cycle without treatment discontinuation due to breakthrough HSR. This definition reflects MSK's current clinical decision-making approach.
resultsA total of 142 patients met inclusion criteria. The median age was 62 years and 103 (73%) were female. Overall RDD success was 92.3%, (131 patients). Breakthrough HSRs occurred in 23% of patients and 19 patients (13.4%) subsequently discontinued the agent. Biomarker-based phenotyping was feasible in 26 patients; incomplete sampling due to workflow limitations precluded classification in the remaining cases.
conclusionsMSK's outpatient RDD protocols demonstrate consistently high success rates across a broad spectrum of chemotherapy and biologic agents, exceeding earlier institutional experience. Increased interdisciplinary collaboration, expanding institutional expertise and refined protocol tailoring represent key advances. Future work should prioritise biomarker-driven approaches and standardised workflows to support consistent biomarker collection, thereby improving phenotype classification and enhancing mechanistic insight to guide individualised desensitisation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.